Long-term management of major depressive disorder: Are differences among antidepressant treatments meaningful?

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 17, 2004, Pages 29-33

  Shelton, Charles I ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS; LONG-TERM CARE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 16644387347     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995;4:261-277
2. Lin EH, Katon WJ, VonKorff M, et al. Relapse of depression in primary care: rate and clinical predictors. Arch Fam Med 1998;7:443-449
3. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156:1000-1006
4. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: 1093-1099
5. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504
6. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry 2000;157(suppl 4):1-45
7. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2: Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
8. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(5, suppl):28-34
9. Keller MB. The long-term treatment of depression. J Clin Psychiatry 1999;60(suppl 17):41-45
10. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-661
11. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25: 1171-1180
12. Simon GE. Long-term prognosis of depression in primary care. Bull World Health Organ 2000;78:439-445
13. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. Am J Psychiatry 2000;157:1243-1251
14. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
15. Campbell S, Marriott M, Nahmias C, et al. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004;161:598-607
16. Steffens DC, Byrum CE, McQuoid DR, et al. Hippocampal volume in geriatric depression. Biol Psychiatry 2000;48:301-309
17. Mervaala E, Fohr J, Kononen M, et al. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med 2000;30:117-125
18. Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000;157:115-118
19. Sheline YI, Wang PW, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996;93:3908-3913
20. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999;19:5034-5043
21. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003;160:1516-1518
22. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301: 805-809
23. Sassi RB, Nicoletti M, Brambilla P, et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002;329:243-245
24. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
25. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998;13:63-73
26. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-49
27. Simon JS, Aguiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004;38:249-257
28. Montgomery SA, Entsuah R, Hackett D, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004;65:328-336
29. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64:1237-1244
30. Detke M, Gilaberte G, Perahia DG. Duloxetine vs placebo in the prevention of relapse of major depressive disorder [poster]. Presented at the 16th annual congress of the European College of Neuropsychopharmacology; September 20-24, 2003; Prague, Czech Republic
31. Kelsey JE, Entsuah AR. Venlafaxine offers significant therapeutic benefits over existing SSRI treatments irrespective of the patients depression duration [abstract]. Int J Neuropsychopharmacol 2002;5(suppl):S207
32. Kelsey J, Entsuah R. Venlafaxine offers significant therapeutic benefits over existing SSRI treatments irrespective of the patient's depressive duration [poster]. Presented at the 23rd annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 23-27, 2002; Montreal, Canada
33. Benattia I, Musgnung J, Graepel J. Remission rates among depressed patients treated with venlafaxine XR or SSRIs using treatment algorithms [poster]. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-5, 2004; New York, NY
34. Thase ME. Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 1999;60(suppl 6):15-19
35. Thase ME. How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry 1999;60(suppl 4):23-31
36. Thase ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull 2002;36:4-17
37. Thase M, Howland RH, Friedman E. Onset of action of selective and multi-action antidepressants. In: den Boer JA, Westenberg H, eds. Antidepressants: Selectivity or Multiplicity? Amsterdam, the Netherlands: Benecke NI; 2001:101-116
38. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21
39. Kunz NR, Entsuah R, Lei D, et al. Venlafaxine extended release XR is superior to placebo in relapse prevention for patients with major depressive disorder [poster]. Presented at the 10th Congress of the Association of European Psychiatrists; October 28-November 1, 2000; Prague, Czech Republic